Literature DB >> 30410281

BaxdelaTM (Delafloxacin): A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

Alexandra Adler, Saira Chaudhry, Tamara Goldberg.   

Abstract

Baxdela (delafloxacin) for treatment of acute bacterial skin and skin structure infections.

Entities:  

Year:  2018        PMID： 30410281      PMCID： PMC6205123     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  21 in total

1.  In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.

Authors:  Laurel S Almer; Jennifer B Hoffrage; Erika L Keller; Robert K Flamm; Virginia D Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

2.  Outcomes and management costs in patients hospitalized for skin and skin-structure infections.

Authors:  Kamal M F Itani; Sanjay Merchant; Swu-Jane Lin; Kasem Akhras; Juan Carlos Alandete; Hind T Hatoum
Journal:  Am J Infect Control       Date:  2010-07-29       Impact factor: 2.918

3.  Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.

Authors:  Randall Hoover; Thomas Hunt; Michael Benedict; Susan K Paulson; Laura Lawrence; Sue Cammarata; Eugene Sun
Journal:  Clin Ther       Date:  2015-12-21       Impact factor: 3.393

4.  The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin.

Authors:  Susan K Paulson; Rebecca N Wood-Horrall; Randall Hoover; Megan Quintas; Laura E Lawrence; Sue K Cammarata
Journal:  Clin Ther       Date:  2017-05-09       Impact factor: 3.393

5.  A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections.

Authors:  William O'Riordan; Purvi Mehra; Paul Manos; Jeff Kingsley; Laura Lawrence; Sue Cammarata
Journal:  Int J Infect Dis       Date:  2014-10-30       Impact factor: 3.623

6.  In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.

Authors:  Angela M Nilius; Linus L Shen; Dena Hensey-Rudloff; Laurel S Almer; Jill M Beyer; Darlene J Balli; Yingna Cai; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

7.  Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age.

Authors:  Randall Hoover; Thomas Hunt; Michael Benedict; Susan K Paulson; Laura Lawrence; Sue Cammarata; Eugene Sun
Journal:  Clin Ther       Date:  2015-11-12       Impact factor: 3.393

Review 8.  Mechanism of quinolone action and resistance.

Authors:  Katie J Aldred; Robert J Kerns; Neil Osheroff
Journal:  Biochemistry       Date:  2014-03-07       Impact factor: 3.162

9.  A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin.

Authors:  Jeff Kingsley; Purvi Mehra; Laura E Lawrence; Eugenia Henry; Erin Duffy; Sue K Cammarata; John Pullman
Journal:  J Antimicrob Chemother       Date:  2015-12-17       Impact factor: 5.790

10.  Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.

Authors:  J Pullman; J Gardovskis; B Farley; E Sun; M Quintas; L Lawrence; R Ling; S Cammarata
Journal:  J Antimicrob Chemother       Date:  2017-12-01       Impact factor: 5.790
View more
  1 in total

1.  Comparison of In Vitro Susceptibility of Delafloxacin with Ciprofloxacin, Moxifloxacin, and Other Comparator Antimicrobials against Isolates of Nontuberculous Mycobacteria.

Authors:  Barbara A Brown Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.